171 related articles for article (PubMed ID: 34003539)
1. Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience.
Kisioglu SV; Demir AS; Tufekci D; Emur Gunay Y; Coskun H; Ucuncu O; Nuhoglu I; Kocak M; Karakullukcu S; Ersoz HO
Int J Clin Pract; 2021 Sep; 75(9):e14377. PubMed ID: 34003539
[TBL] [Abstract][Full Text] [Related]
2. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
[TBL] [Abstract][Full Text] [Related]
3. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and safety of insulin degludec/aspart (twice-daily injections), insulin glargine 300 U/mL, and insulin glulisine (basal-bolus therapy).
Kawaguchi Y; Sawa J; Hamai C; Nishimura Y; Kumeda Y
J Diabetes Investig; 2019 Nov; 10(6):1527-1536. PubMed ID: 30868726
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparison of efficacy and safety of insulin glargine/lixisenatide and insulin degludec/insulin aspart in type 2 diabetes patients not controlled on basal insulin.
Jammah AA
Prim Care Diabetes; 2021 Feb; 15(1):132-137. PubMed ID: 32839127
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy and safety of once-daily insulin degludec/insulin aspart (IDegAsp) and long-acting second-generation basal insulin (insulin degludec and insulin glargine 300 units/mL) in insulin-naïve Japanese adults with type 2 diabetes: a pilot, randomized, controlled study.
Shimoda S; Sakamoto W; Hokamura A; Matsuo Y; Sekigami T; Ichimori S; Iwashita S; Ishii N; Otsu K; Yoshimura R; Nishiyama T; Sakaguchi M; Nishida K; Araki E
Endocr J; 2019 Aug; 66(8):745-752. PubMed ID: 31308304
[TBL] [Abstract][Full Text] [Related]
7. Low fasting glucose-to-estimated average glucose ratio was associated with superior response to insulin degludec/aspart compared with basal insulin in patients with type 2 diabetes.
Jang HN; Yang YS; Oh TJ; Koo BK; Lee SO; Park KS; Jang HC; Jung HS
J Diabetes Investig; 2022 Jan; 13(1):85-93. PubMed ID: 34291584
[TBL] [Abstract][Full Text] [Related]
8. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes.
Güneş E; Güneş M
Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6691-6699. PubMed ID: 37522680
[TBL] [Abstract][Full Text] [Related]
10. Favorable Glycemic Control with Once-Daily Insulin Degludec/Insulin Aspart after Changing from Basal Insulin in Adults with Type 2 Diabetes.
Jang HN; Yang YS; Lee SO; Oh TJ; Koo BK; Jung HS
Endocrinol Metab (Seoul); 2019 Dec; 34(4):382-389. PubMed ID: 31884738
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
[TBL] [Abstract][Full Text] [Related]
12. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
Aso Y; Takada Y; Tomotsune K; Chiba Y; Matsumura M; Jojima T; Sato M; Fujita N; Kuroda H; Murano S; Usui I
Int J Clin Pract; 2021 Apr; 75(4):e13734. PubMed ID: 33099848
[TBL] [Abstract][Full Text] [Related]
13. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial.
Onishi Y; Ono Y; Rabøl R; Endahl L; Nakamura S
Diabetes Obes Metab; 2013 Sep; 15(9):826-32. PubMed ID: 23557077
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST
Hirsch IB; Franek E; Mersebach H; Bardtrum L; Hermansen K
Diabet Med; 2017 Feb; 34(2):167-173. PubMed ID: 26773446
[TBL] [Abstract][Full Text] [Related]
15. ARISE-a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design.
Fulcher GR; Jarlov H; Piltoft JS; Singh KP; Liu L; Mohamed M; Nicodemus NA; Al-Jaser SJ; Kok A
Endocrine; 2021 Dec; 74(3):530-537. PubMed ID: 34637072
[TBL] [Abstract][Full Text] [Related]
16. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.
Mehta R; Chen R; Hirose T; John M; Kok A; Lehmann R; Unnikrishnan AG; Yavuz DG; Fulcher G
Diabetes Obes Metab; 2020 Nov; 22(11):1961-1975. PubMed ID: 32618405
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of once-daily insulin degludec/insulin aspart compared with once-daily insulin glargine in participants with Type 2 diabetes: a randomized, treat-to-target study.
Kumar S; Jang HC; Demirağ NG; Skjøth TV; Endahl L; Bode B
Diabet Med; 2017 Feb; 34(2):180-188. PubMed ID: 27027878
[TBL] [Abstract][Full Text] [Related]
18. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
[TBL] [Abstract][Full Text] [Related]
19. Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Kalra S; Atkin S; Cervera A; Das AK; Demir O; Demir T; Fariduddin M; Vo KT; Ku BJ; Kumar A; Latif ZA; Malek R; Matawaran BJ; Mehta R; Tran NQ; Panelo A; Ruder S; Saldana JR; Shaikh KA; Shakya A; Shrestha D; Unnikrishnan AG
Adv Ther; 2018 Jul; 35(7):928-936. PubMed ID: 29796928
[TBL] [Abstract][Full Text] [Related]
20. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.
Garber AJ; King AB; Del Prato S; Sreenan S; Balci MK; Muñoz-Torres M; Rosenstock J; Endahl LA; Francisco AM; Hollander P;
Lancet; 2012 Apr; 379(9825):1498-507. PubMed ID: 22521072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
